PHAXIAM Therapeutics presents an ambitious development strategy to take advantage of the rapidly evolving Phages therapy area
Webinar being held today "Evolving strategic context for phages, Introducing new opportunities" to present PHAXIAM Therapeutics strategyBased on the positive evolution in phages therapy market, PHAXIAM’s development strategy could allow the Company to reach operating profitability and positive free cash flow in 2027 Lyon (France) – November 27, 2024, at 02:30 p.m. CET – PHAXIAM Therapeutics (Euronext: PHXM - FR0011471135), a biopharmaceutical company developing innovative treatments for severe and resistant ...